Eton Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Eton Pharmaceuticals, Inc. (ETON) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $21.25 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-13
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was -$3.45M.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $3.47M, a 197.60% increase year-over-year.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $1.85M, a 0.76% decline year-over-year.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was -$1.17M.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $1.85M, a 0.80% decline from fiscal 2024.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $1.87M, a 205.07% increase from fiscal 2023.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $612.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$3.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $21.25K 10-Q · filed 2026-08-13 | $1.87M derived: sum of 3 quarters · filed 2026-08-13 | $706.25K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $3.47M 10-Q · filed 2026-05-14 | $5.32M derived: sum of 2 quarters · filed 2026-05-14 | $4.16M derived: sum of 3 quarters · filed 2026-05-14 | $4.16M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $1.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $685.00K derived: sum of 2 quarters · filed 2026-03-19 | $685.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.85M 10-K · filed 2026-03-19 | |
| 2025-09-30 | -$1.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.17M derived: sum of 2 quarters · filed 2026-08-13 | $1.17K 10-Q · filed 2025-11-06 | $1.87M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.17M 10-Q · filed 2026-08-13 | $3.03M derived: sum of 3 quarters · filed 2026-08-13 | $3.03M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $1.17M 10-Q · filed 2026-05-14 | $1.17K 10-Q · filed 2025-05-13 | $3.03M derived: sum of 2 quarters · filed 2026-05-14 | $3.03M derived: sum of 3 quarters · filed 2026-05-14 | $3.03M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $1.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.86M derived: sum of 2 quarters · filed 2026-03-19 | $1.86M derived: sum of 3 quarters · filed 2026-03-19 | $1.87M 10-K · filed 2026-03-19 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $2.00K 10-Q · filed 2025-11-06 | $3.00K derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.00K 10-Q · filed 2025-08-07 | $3.00K derived: sum of 3 quarters · filed 2025-08-07 | $13.00K derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $2.00K 10-Q · filed 2025-05-13 | $3.00K derived: sum of 2 quarters · filed 2025-05-13 | $13.00K derived: sum of 3 quarters · filed 2025-05-13 | $13.00K derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $11.00K derived: sum of 2 quarters · filed 2024-03-14 | $11.00K derived: sum of 3 quarters · filed 2024-03-14 | $612.00K 10-K · filed 2024-03-14 | |
| 2023-09-30 | $10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $10.00K derived: sum of 2 quarters · filed 2023-11-09 | $611.00K 10-Q · filed 2023-11-09 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $601.00K 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $601.00K 10-Q · filed 2023-05-11 | ||||
| 2022-09-30 | $31.00K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |